Chemokines as mediators of tumor angiogenesis and neovascularization

Experimental Cell Research

Volumn 317, Issue 5, 2011, Pages 685-690

  Keeley, Ellen C ^a   Mehrad, Borna ^a   Strieter, Robert M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Angiogenesis; Cancer; Chemokines

Indexed keywords

CCL16 CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR CXCR3; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL4 CHEMOKINE; CXCL7 CHEMOKINE; CXCL9 CHEMOKINE; EOTAXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; CARCINOGENESIS; HUMAN; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 79952103672     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.10.020     Document Type: Review

References (76)

1. Silvestre J.S., Mallat Z., Tedgui A., Levy B.I. Post-ischaemic neovascularization and inflammation. Cardiovasc. Res. 2008, 78:242-249.
2. Mehrad B., Keane M.P., Strieter R.M. Chemokines as mediators of angiogenesis. Thromb. Haemost. 2007, 97:755-762.
3. Keeley E.C., Mehrad B., Strieter R.M. Chemokines as mediators of neovascularization. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1928-1936.
4. Chemokine/chemokine receptor nomenclature. Cytokine 2003, 21:48-49.
5. Addison C.L., Daniel T.O., Burdick M.D., Liu H., Ehlert J.E., Xue Y.Y., Buechi L., Walz A., Richmond A., Strieter R.M. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J. Immunol. 2000, 165:5269-5277.
6. Murdoch C., Monk P.N., Finn A. Cxc chemokine receptor expression on human endothelial cells. Cytokine 1999, 11:704-712.
7. Heidemann J., Ogawa H., Dwinell M.B., Rafiee P., Maaser C., Gockel H.R., Otterson M.F., Ota D.M., Lugering N., Domschke W., Binion D.G. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J. Biol. Chem. 2003, 278:8508-8515.
8. Hristov M., Zernecke A., Bidzhekov K., Liehn E.A., Shagdarsuren E., Ludwig A., Weber C. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ. Res. 2007, 100:590-597.
9. Kocher A.A., Schuster M.D., Bonaros N., Lietz K., Xiang G., Martens T.P., Kurlansky P.A., Sondermeijer H., Witkowski P., Boyle A., Homma S., Wang S.F., Itescu S. Myocardial homing and neovascularization by human bone marrow angioblasts is regulated by IL-8/Gro CXC chemokines. J. Mol. Cell. Cardiol. 2006, 40:455-464.
10. Addison C.L., Belperio J.A., Burdick M.D., Strieter R.M. Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer 2004, 4:28.
11. Keane M.P., Belperio J.A., Xue Y.Y., Burdick M.D., Strieter R.M. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J. Immunol. 2004, 172:2853-2860.
12. Du J., Luan J., Liu H., Daniel T.O., Peiper S., Chen T.S., Yu Y., Horton L.W., Nanney L.B., Strieter R.M., Richmond A. Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. J. Leukoc. Biol. 2002, 71:141-153.
13. Shen H., Schuster R., Stringer K.F., Waltz S.E., Lentsch A.B. The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J. 2006, 20:59-64.
14. Galvez B.G., Genis L., Matias-Roman S., Oblander S.A., Tryggvason K., Apte S.S., Arroyo A.G. Membrane type 1-matrix metalloproteinase is regulated by chemokines monocyte-chemoattractant protein-1/ccl2 and interleukin-8/CXCL8 in endothelial cells during angiogenesis. J. Biol. Chem. 2005, 280:1292-1298.
15. Stamatovic S.M., Keep R.F., Mostarica-Stojkovic M., Andjelkovic A.V. CCL2 regulates angiogenesis via activation of Ets-1 transcription factor. J. Immunol. 2006, 177:2651-2661.
16. Weber K.S., Nelson P.J., Grone H.J., Weber C. Expression of CCR2 by endothelial cells: implications for MCP-1 mediated wound injury repair and In vivo inflammatory activation of endothelium. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2085-2093.
17. Barcelos L.S., Talvani A., Teixeira A.S., Cassali G.D., Andrade S.P., Teixeira M.M. Production and in vivo effects of chemokines CXCL1-3/KC and CCL2/JE in a model of inflammatory angiogenesis in mice. Inflamm. Res. 2004, 53:576-584.
18. Goede V., Brogelli L., Ziche M., Augustin H.G. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int. J. Cancer 1999, 82:765-770.
19. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., Oppenheim J.J., Murphy W.J. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96:34-40.
20. Fujiyama S., Amano K., Uehira K., Yoshida M., Nishiwaki Y., Nozawa Y., Jin D., Takai S., Miyazaki M., Egashira K., Imada T., Iwasaka T., Matsubara H. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ. Res. 2003, 93:980-989.
21. Hong K.H., Ryu J., Han K.H. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 2005, 105:1405-1407.
22. Niu J., Azfer A., Zhelyabovska O., Fatma S., Kolattukudy P.E. Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP). J. Biol. Chem. 2008, 283:14542-14551.
23. Salcedo R., Young H.A., Ponce M.L., Ward J.M., Kleinman H.K., Murphy W.J., Oppenheim J.J. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J. Immunol. 2001, 166:7571-7578.
24. Strasly M., Doronzo G., Cappello P., Valdembri D., Arese M., Mitola S., Moore P., Alessandri G., Giovarelli M., Bussolino F. CCL16 activates an angiogenic program in vascular endothelial cells. Blood 2004, 103:40-49.
25. Maione T.E., Gray G.S., Petro J., Hunt A.J., Donner A.L., Bauer S.I., Carson H.F., Sharpe R.J. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990, 247:77-79.
26. Gupta S.K., Singh J.P. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J. Cell Biol. 1994, 127:1121-1127.
27. Romagnani P., Annunziato F., Lasagni L., Lazzeri E., Beltrame C., Francalanci M., Uguccioni M., Galli G., Cosmi L., Maurenzig L., Baggiolini M., Maggi E., Romagnani S., Serio M. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest. 2001, 107:53-63.
28. Soto H., Wang W., Strieter R.M., Copeland N.G., Gilbert D.J., Jenkins N.A., Hedrick J., Zlotnik A. The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc. Natl Acad. Sci. USA 1998, 95:8205-8210.
29. Beider K., Nagler A., Wald O., Franitza S., Dagan-Berger M., Wald H., Giladi H., Brocke S., Hanna J., Mandelboim O., Darash-Yahana M., Galun E., Peled A. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood 2003, 102:1951-1958.
30. Loetscher M., Gerber B., Loetscher P., Jones S.A., Piali L., Clark-Lewis I., Baggiolini M., Moser B. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 1996, 184:963-969.
31. Loetscher M., Loetscher P., Brass N., Meese E., Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur. J. Immunol. 1998, 28:3696-3705.
32. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J. Med. 1998, 338:436-445.
33. Moser B., Loetscher P. Lymphocyte traffic control by chemokines. Nat. Immunol. 2001, 2:123-128.
34. Qin S., Rottman J.B., Myers P., Kassam N., Weinblatt M., Loetscher M., Koch A.E., Moser B., Mackay C.R. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 1998, 101:746-754.
35. Rabin R.L., Park M.K., Liao F., Swofford R., Stephany D., Farber J.M. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J. Immunol. 1999, 162:3840-3850.
36. Lasagni L., Francalanci M., Annunziato F., Lazzeri E., Giannini S., Cosmi L., Sagrinati C., Mazzinghi B., Orlando C., Maggi E., Marra F., Romagnani S., Serio M., Romagnani P. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 2003, 197:1537-1549.
37. Salcedo R., Resau J.H., Halverson D., Hudson E.A., Dambach M., Powell D., Wasserman K., Oppenheim J.J. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J. 2000, 14:2055-2064.
38. Ehlert J.E., Addison C.A., Burdick M.D., Kunkel S.L., Strieter R.M. Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J. Immunol. 2004, 173:6234-6240.
39. Burdick M.D., Murray L.A., Keane M.P., Xue Y.Y., Zisman D.A., Belperio J.A., Strieter R.M. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am. J. Respir. Crit. Care Med. 2005, 171:261-268.
40. Yang J., Richmond A. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol. Ther. 2004, 9:846-855.
41. Moser M. Regulation of Th1/Th2 development by antigen-presenting cells in vivo. Immunobiology 2001, 204:551-557.
42. Pan J., Burdick M.D., Belperio J.A., Xue Y.Y., Gerard C., Sharma S., Dubinett S.M., Strieter R.M. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J. Immunol. 2006, 176:1456-1464.
43. Strieter R.M., Belperio J.A., Burdick M.D., Sharma S., Dubinett S.M., Keane M.P. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann. NY Acad. Sci. 2004, 1028:351-360.
44. Tannenbaum C.S., Tubbs R., Armstrong D., Finke J.H., Bukowski R.M., Hamilton T.A. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 1998, 161:927-932.
45. Sharma S., Stolina M., Luo J., Strieter R.M., Burdick M., Zhu L.X., Batra R.K., Dubinett S.M. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. 2000, 164:4558-4563.
46. Sharma S., Yang S.C., Hillinger S., Zhu L.X., Huang M., Batra R.K., Lin J.F., Burdick M.D., Strieter R.M., Dubinett S.M. SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol. Cancer 2003, 2:22.
47. Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. Semin. Thromb. Hemost. 2004, 30:379-385.
48. Bikfalvi A., Gimenez-Gallego G. The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules. Semin. Thromb. Hemost. 2004, 30:137-144.
49. Perollet C., Han Z.C., Savona C., Caen J.P., Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 1998, 91:3289-3299.
50. Arenberg D.A., Kunkel S.L., Polverini P.J., Morris S.B., Burdick M.D., Glass M.C., Taub D.T., Iannettoni M.D., Whyte R.I., Strieter R.M. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 1996, 184:981-992.
51. Loscalzo J., Melnick B., Handin R.I. The interaction of platelet factor four and glycosaminoglycans. Arch. Biochem. Biophys. 1985, 240:446-455.
52. Struyf S., Burdick M.D., Proost P., Van Damme J., Strieter R.M. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ. Res. 2004, 95:855-857.
53. Struyf S., Burdick M.D., Peeters E., Van den Broeck K., Dillen C., Proost P., Van Damme J., Strieter R.M. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res. 2007, 67:5940-5948.
54. Salcedo R., Wasserman K., Young H.A., Grimm M.C., Howard O.M., Anver M.R., Kleinman H.K., Murphy W.J., Oppenheim J.J. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. Am. J. Pathol. 1999, 154:1125-1135.
55. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
56. Phillips R.J., Burdick M.D., Lutz M., Belperio J.A., Keane M.P., Strieter R.M. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am. J. Respir. Crit. Care Med. 2003, 167:1676-1686.
57. Arenberg D.A., Kunkel S.L., Polverini P.J., Glass M., Burdick M.D., Strieter R.M. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest. 1996, 97:2792-2802.
58. Smith D.R., Polverini P.J., Kunkel S.L., Orringer M.B., Whyte R.I., Burdick M.D., Wilke C.A., Strieter R.M. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J. Exp. Med. 1994, 179:1409-1415.
59. Yatsunami J., Tsuruta N., Ogata K., Wakamatsu K., Takayama K., Kawasaki M., Nakanishi Y., Hara N., Hayashi S. Interleukin-8 participates in angiogenesis in non-small cell, but not small cell carcinoma of the lung. Cancer Lett. 1997, 120:101-108.
60. Wislez M., Fujimoto N., Izzo J.G., Hanna A.E., Cody D.D., Langley R.R., Tang H., Burdick M.D., Sato M., Minna J.D., Mao L., Wistuba I., Strieter R.M., Kurie J.M. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res. 2006, 66:4198-4207.
61. White E.S., Flaherty K.R., Carskadon S., Brant A., Iannettoni M.D., Yee J., Orringer M.B., Arenberg D.A. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin. Cancer Res. 2003, 9:853-860.
62. Chen J.J., Yao P.L., Yuan A., Hong T.M., Shun C.T., Kuo M.L., Lee Y.C., Yang P.C. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin. Cancer Res. 2003, 9:729-737.
63. Wente M.N., Keane M.P., Burdick M.D., Friess H., Buchler M.W., Ceyhan G.O., Reber H.A., Strieter R.M., Hines O.J. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett. 2006, 241:221-227.
64. Arenberg D.A., White E.S., Burdick M.D., Strom S.R., Strieter R.M. Improved survival in tumor-bearing SCID mice treated with interferon-gamma-inducible protein 10 (IP-10/CXCL10). Cancer Immunol. Immunother. 2001, 50:533-538.
65. Wang D., Wang H., Brown J., Daikoku T., Ning W., Shi Q., Richmond A., Strieter R., Dey S.K., DuBois R.N. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J. Exp. Med. 2006, 203:941-951.
66. Takamori H., Oades Z.G., Hoch O.C., Burger M., Schraufstatter I.U. Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1. Pancreas 2000, 21:52-56.
67. Yoneda J., Kuniyasu H., Crispens M.A., Price J.E., Bucana C.D., Fidler I.J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl Cancer Inst. 1998, 90:447-454.
68. Gawrychowski K., Skopinska-Rozewska E., Barcz E., Sommer E., Szaniawska B., Roszkowska-Purska K., Janik P., Zielinski J. Angiogenic activity and interleukin-8 content of human ovarian cancer ascites. Eur. J. Gynaecol. Oncol. 1998, 19:262-264.
69. Bostwick D.G., Iczkowski K.A. Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin. Urol. Oncol. 1998, 16:118-123.
70. Fregene T.A., Khanuja P.S., Noto A.C., Gehani S.K., Van Egmont E.M., Luz D.A., Pienta K.J. Tumor-associated angiogenesis in prostate cancer. Anticancer Res. 1993, 13:2377-2381.
71. Kim S.J., Uehara H., Karashima T., McCarty M., Shih N., Fidler I.J. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 2001, 3:33-42.
72. Moore B.B., Arenberg D.A., Stoy K., Morgan T., Addison C.L., Morris S.B., Glass M., Wilke C., Xue Y.Y., Sitterding S., Kunkel S.L., Burdick M.D., Strieter R.M. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am. J. Pathol. 1999, 154:1503-1512.
73. Charalambous C., Chen T.C., Hofman F.M. Characteristics of tumor-associated endothelial cells derived from glioblastoma multiforme. Neurosurg. Focus 2006, 20:E22.
74. Garkavtsev I., Kozin S.V., Chernova O., Xu L., Winkler F., Brown E., Barnett G.H., Jain R.K. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004, 428:328-332.
75. Luan J., Shattuck-Brandt R., Haghnegahdar H., Owen J.D., Strieter R., Burdick M., Nirodi C., Beauchamp D., Johnson K.N., Richmond A. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J. Leukoc. Biol. 1997, 62:588-597.
76. Mestas J., Burdick M.D., Reckamp K., Pantuck A., Figlin R.A., Strieter R.M. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J. Immunol. 2005, 175:5351-5357.